欧洲下一代抗体市场预测至 2028 年 - 按治疗领域（肿瘤学、自身免疫或炎症）和技术（抗体药物偶联物、双特异性抗体、Fc 工程抗体、抗体片段和抗体样蛋白）进行的 COVID-19 影响和区域分析和生物类似抗体产品）
No. of Pages: 123 | Report Code: TIPRE00028000 | Category: Life Sciences
No. of Pages: 123 | Report Code: TIPRE00028000 | Category: Life Sciences
癌症患病率的不断上升以及对下一代抗体疗法的需求不断增长正在推动欧洲下一代抗体的发展市场。然而，与下一代抗体的制造和批准相关的复杂性预计将限制预测期内的市场增长。
生物技术的不断发展导致人们对抗体的接受度不断提高下一代抗体疗法，进一步推动其在自身免疫、炎症和慢性疾病治疗中的应用。下一代抗体治疗是抗体治疗中复杂技术应用的结果，例如抗体药物偶联物 (ADC)、糖工程抗体和特异性抗体 (BsAb)。因此，人们正在广泛研究下一代抗体的应用，以治疗各种慢性疾病。
对这些抗体的需求不断增长，导致ADC和ADC的批准量迅速增加其他下一代抗体疗法。例如，2020年5月，武田药品工业株式会社宣布 FDA 批准 ALUNBRIG（brigatinib）用于治疗经 FDA 批准的测试检测到的间变性淋巴瘤激酶阳性（ALK+）转移性非小细胞肺癌（NSCLC）成人患者。经批准，ALUNBRIG 目前的适应症已扩大到涵盖一线治疗。它是下一代酪氨酸激酶抑制剂（TKI），旨在针对 ALK 分子异常。
同样，2019 年，基因泰克宣布 FDA 加速批准 Polatuzumab vedotin-piiq，这是一种CD79b 导向的抗体药物偶联物与苯达莫司汀和利妥昔单抗产品联合用于治疗复发或难治性弥漫性大 B 细胞淋巴瘤的成年患者。
此外，未来的投资不断增加来自生物制药和制药公司的新一代抗体制造和开发这些下一代抗体正在推动市场。此外，合同制造和开发组织 (CDMO) 与下一代抗体偶联物建立联系，以提供更全面的 ADC 功能。 CDMO 正在开发位点特异性连接技术，扩大其有效负载选项，并针对癌症以外的适应症进行规划。例如，2020 年 9 月，MilliporeSigma 宣布斥资 6500 万美元扩大其位于麦迪逊（威斯康星州）工厂的高效活性药物成分 (HPAPI) 和活性药物成分的生产能力和产能。
同样，2019 年 7 月，REGENXBIO 和 Neurimmune AG 签署了一项许可、开发和商业化合作，以开发创新的 AV 基因治疗方法，利用 NAV 载体提供针对慢性神经退行性疾病（例如 tau蛋白病）的人类抗体。< /span>
因此，由于临床试验批准的增加以及下一代抗体疗法治疗各种疾病的广泛采用，预计下一代抗体市场将在预测期内激增。
由于 COVID-19 病例呈指数级增长，欧洲经济受到严重影响。西班牙、意大利、德国、法国和英国是受影响最严重的欧洲国家，死亡人数也很高。多家公司在2019年最后一个季度出现严重亏损，也对2020年第一季度和第二季度产生了负面影响。因此，COVID-19对欧洲市场的影响是直接而剧烈的。物流本来就复杂的下一代抗体供应链面临着新的挑战。在 COVID-19 危机之初，由于大多数欧洲国家宣布封锁导致供应链和需求中断，下一代抗体市场也出现了一些短缺。然而，由于未来几年政府的支持举措，对下一代抗体的需求预计将会增加。
Strategic insights for Europe Next-generation Antibody involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,455.32 Million |
| Market Size by 2028 | US$ 3,162.30 Million |
| Global CAGR (2021 - 2028) | 11.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 治疗领域
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Next-generation Antibody refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Next-generation Antibody Market is valued at US$ 1,455.32 Million in 2021, it is projected to reach US$ 3,162.30 Million by 2028.
As per our report Europe Next-generation Antibody Market, the market size is valued at US$ 1,455.32 Million in 2021, projecting it to reach US$ 3,162.30 Million by 2028. This translates to a CAGR of approximately 11.7% during the forecast period.
The Europe Next-generation Antibody Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Next-generation Antibody Market report:
The Europe Next-generation Antibody Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Next-generation Antibody Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Next-generation Antibody Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Next-generation Antibody Market
